Semaglutide Shows Significant Benefits in Binge Eating Treatment
A recent study reveals that semaglutide significantly improves binge eating symptoms and body image in adults compared to placebo.
Participants on semaglutide lost an average of 15% of body weight over 60 weeks.
The medication led to notable reductions in binge eating episodes and body dissatisfaction.
Ongoing monitoring is essential for individuals with a history of eating disorders.
A study conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that semaglutide, a medication used for obesity treatment, significantly improves symptoms of binge eating and body dissatisfaction in adults. The findings were published in the International Journal of Eating Disorders and presented at ObesityWeek 2026 in Washington, D.C.
The research involved 120 adults who were randomly assigned to receive either semaglutide at a dosage of 2.4 mg or a placebo, alongside a structured lifestyle intervention that included dietary counseling and physical activity guidance. After 60 weeks, participants taking semaglutide experienced an average weight loss of approximately 15%, compared to about 3% in the placebo group, indicating a strong correlation between the medication and effective weight management.
Throughout the study, those treated with semaglutide reported significant improvements in various aspects of eating-related and psychological health. The medication was linked to greater reductions in loss-of-control eating, overall eating disorder symptoms, and concerns about body weight and shape. Additionally, participants noted enhanced feelings of body image and reduced body dissatisfaction.
Among those entering the study with binge eating episodes, individuals receiving semaglutide were more likely to achieve remission from binge eating behaviors. The study indicated that the emergence of new eating disorder symptoms was rare in both treatment groups, suggesting that semaglutide generally led to positive outcomes rather than exacerbating existing issues.
The researchers emphasized the need for continued monitoring of eating behaviors, especially for participants with a history of eating disorders. They acknowledged that while the average outcomes were promising, a small number of participants did experience disordered eating behaviors. Future research with larger sample sizes is necessary to further explore the relationship between GLP-1 medications like semaglutide and eating disorders, particularly for those diagnosed with binge eating disorder.




